Purple Biotech (PPBT) Debt Ratio (2017 - 2020)

Purple Biotech (PPBT) reported Debt Ratio of 0.28 for Q2 2020, up 99.53% year-over-year from 0.14 in Q3 2019, and up 99.53% quarter-over-quarter from 0.14 in Q2 2019.

Purple Biotech (PPBT) Debt Ratio (2017 - 2020) Analysis & Trends

Purple Biotech (PPBT) has 4 years of Debt Ratio data on file, last reported at 0.28 in Q2 2020.

  • Debt Ratio for Q2 2020 came in at 0.28, up 99.53% year-over-year; the trailing twelve-month figure through Jun 2020 was 0.28 (up 99.53% YoY), and the FY2018 annual result was 0.04, down 73.48% from the prior year.
  • Debt Ratio improved to 0.28 in Q2 2020 per PPBT's latest filing, from 0.14 in the prior quarter.
  • Over five years, Debt Ratio peaked at 0.28 in Q2 2020 and troughed at 0.04 in Q4 2018.
  • A 4-year average of 0.15 and a median of 0.14 in 2017 frame the typical range for Debt Ratio.
  • On a YoY basis, Debt Ratio climbed as much as 254.49% in 2018 and fell as far as 73.48% in 2018.
  • A 4-year view of Debt Ratio shows it stood at 0.14 in 2017, then slumped by 73.48% to 0.04 in 2018, then surged by 278.9% to 0.14 in 2019, then jumped by 99.53% to 0.28 in 2020.
  • Business Quant data shows PPBT's Debt Ratio at 0.28 in Q2 2020, 0.14 in Q2 2019, and 0.04 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 0.18
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Purple Biotech 242.86 Mn 236.43 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2020 0.28
Jun 30, 2019 0.14
Dec 31, 2018 0.04
Jun 30, 2018 0.23
Dec 31, 2017 0.14
Jun 30, 2017 0.07